Back HCV Policy & Advocacy

HCV Policy & Advocacy

Obama Budget Boosts U.S. HIV and Hepatitis Funding, Cuts Global AIDS and TB

President Obama's proposed $4 trillion budget for fiscal year 2016 would increase funding for CDC's viral hepatitis and HIV prevention efforts, boost spending for HIV research, and allocate more to combat antibiotic resistance. The proposal would also change the law to allow Medicare to negotiate prescription drug prices, which could potentially save billions of dollars. But the plan would cut overall global health funding, including support for the Global Fund to Fight AIDS, Malaria, and Tuberculosis. 

alt

Read more:

3. High Hepatitis C Treatment Cost Leads to Restrictions, Sets Off Price War

The high cost of new interferon-free hepatitis C treatments has raised concerns about how public payers and private insurers will be able to afford them and sparked a more general discussion about the cost of pharmaceuticals in a changing healthcare landscape.

alt

Read more:

Obamacare Deadline Coming Up, Guide Offers Covered California Advice for HIV, HCV, PrEP

December 15 is the deadline to enroll in Affordable Care Act (ACA or "Obamacare") health plans for insurance coverage starting on January 1, 2015. Finding the right plan can be tricky for people with HIV or hepatitis C, and for those who want coverage for Truvada for pre-exposure prophylaxis (PrEP), but there are resources to help.

alt

Read more:

AASLD 2014: 1 Million People with Hepatitis C in the U.S. Meet High Priority Criteria for Treatment

An estimated 813,000 people with diagnosed hepatitis C in the U.S. have undergone liver disease staging and meet the "highest" or "high" priority criteria for immediate treatment, according to an analysis presented at the American Association for the Study of Liver Diseases (AASLD) Liver Meeting last month in Boston. The number would be even higher if taking into account undiagnosed individuals and prisoners and others excluded from household surveys.

alt

Read more:

Gilead Announces Generic Licensing Agreements for Hepatitis C Drug Sofosbuvir

Gilead Sciences announced this week that it has granted a license to 7 generic drug companies in India to produce cheaper versions of its groundbreaking hepatitis C polymerase inhibitor sofosbuvir (Sovaldi) and its forthcoming sofosbuvir/ledipasvir coformulation for use in more than 90 developing countries.

alt

Read more: